<DOC>
	<DOCNO>NCT01188278</DOCNO>
	<brief_summary>The purpose study determine predictive value Hammersmith score Complete Cytogenetic Response ( CCyR ) .</brief_summary>
	<brief_title>Treatment With Second Generation Tyrosine Kinase Inhibitors ( 2G TKI ) Post Imatinib Failure Survey</brief_title>
	<detailed_description>Historic cohort prolong 12-month follow-up period . Prospective : look forward use periodic observation collect predominantly follow subject enrollment : one year follow patient CP-CML alive time study . Retrospective : look back use observation collect predominantly prior subject selection enrollment : historical data patient CP-CML initiate 2G TKIs post-imatinib failure ( resistance intolerance ) 1-Jan-2005 30-June-2009 . The inclusion historical cohort allow rapid enrollment large number patient rare pathology , prospective follow cohort would allow long term data obtain , include assessment impact survival appreciate patient 's quality life ( QoL ) , compliance satisfaction .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Patients Additional Chromosomal Anomalies ( ACA ) accept CP . Patients enrol openlabel clinical trial observational trial also allow ( unless explicitly prohibit trial ) . This trial prohibit participation observational trial . Patients diagnose CPCML . ( ACA ) allow Age &gt; 18 year old Prior treatment imatinib monotherapy first line treatment , patient deem resistant intolerant.Patients treat INF and/or AraC prior ( concomitant ) imatinib eligible . Initiated 2G TKIs postimatinib failure ( resistance intolerance ) 1Jan2005 30Jun2009 . Patients ( history ) accelerate blastic phase CML Patients treat allogeneic stem cell transplantation . Any CML treatment except INF and/or AraC , short period Hydroxyurea Anagrelide prior imatinib . Patients treat 2G TKI reason imatinib failure . Patients historical data ( e.g . possibility Sokal Score calculation ) available . Patients participate clinical observational trial explicitly prohibit enrollment non interventional study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>